文献速递炎症性肠病

系统综述与网络荟萃分析:托法替布与生物制剂治疗中重度溃疡性结肠炎的对比评估

Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-04

该系统综述与网络荟萃分析纳入了15项诱导治疗随机双盲安慰剂对照试验(n=3130)和9项维持治疗研究(n=1776),评估托法替布与英夫利西单抗、阿达木单抗、戈利木单抗和维得利珠单抗在未暴露于TNF拮抗剂的成人中重度UC患者中的疗效与危害。间接比较显示英夫利西单抗在临床应答、临床缓解和黏膜愈合方面优于阿达木单抗和/或戈利木单抗,托法替布与生物制剂之间无间接比较达统计学显著;安全性方面除英夫利西单抗外各治疗未增加不良事件率,维得利珠单抗在严重不良事件发生方面可能具有优势。

要点

  • 所有治疗在诱导和维持治疗中均优于安慰剂。
  • 英夫利西单抗在临床应答、缓解和黏膜愈合上优于阿达木单抗和/或戈利木单抗。
  • 托法替布与生物制剂之间无间接比较达统计学显著。

核心结论

  • 托法替布和生物制剂对溃疡性结肠炎有效且安全。
  • 需要进一步高质量研究以确定最佳治疗选择。

研究设计与样本

  • 系统综述与网络荟萃分析,综合直接证据并调整间接治疗比较。
  • 检索PubMed、Embase、Scopus、临床试验注册库、监管机构网站和主要会议论文集,截至2017年8月。
  • 纳入15项诱导治疗随机双盲安慰剂对照试验(n=3130)和9项维持治疗研究(n=1776)。

主要发现

  • 所有治疗在诱导治疗中优于安慰剂。
  • 英夫利西单抗在临床应答上优于阿达木单抗(OR 2.01,95%CI 1.36-2.98)和戈利木单抗(OR 1.67,95%CI 1.08-2.59)。
  • 英夫利西单抗在临床缓解上优于阿达木单抗(OR 2.10,95%CI 1.21-3.64)。
  • 英夫利西单抗在黏膜愈合上优于阿达木单抗(OR 1.87,95%CI 1.26-2.79)和戈利木单抗(OR 1.75,95%CI 1.13-2.73)。
  • 托法替布与生物制剂之间无间接比较达统计学显著;维持治疗中所有治疗临床疗效均高于安慰剂;安全性分析显示除英夫利西单抗外各治疗未增加不良事件率,维得利珠单抗在严重不良事件发生方面可能具有优势。

关键数值与推荐

  • 英夫利西单抗 vs 阿达木单抗临床应答OR 2.01(95%CI 1.36-2.98)。
  • 英夫利西单抗 vs 戈利木单抗临床应答OR 1.67(95%CI 1.08-2.59)。
  • 英夫利西单抗 vs 阿达木单抗临床缓解OR 2.10(95%CI 1.21-3.64)。
  • 英夫利西单抗 vs 阿达木单抗黏膜愈合OR 1.87(95%CI 1.26-2.79)。
  • 英夫利西单抗 vs 戈利木单抗黏膜愈合OR 1.75(95%CI 1.13-2.73)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步高质量研究以确定最佳治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological therapies have improved the care of patients with ulcerative colitis (UC). Tofacitinib, an oral small-molecule Janus kinase inhibitor, is potentially a new treatment option. AIM: To comparatively assess efficacy and harm of tofacitinib and biologics (infliximab, adalimumab, golimumab and vedolizumab) in adult patients not previously exposed to TNF antagonists. METHODS: We performed a comprehensive search of PubMed, Embase, Scopus, clinical trial registries, regulatory authorities' websites and major conference proceedings, through August 2017, to identify randomised, placebo-controlled or head-to-head trials assessing tofacitinib or biologics as induction and/or maintenance therapy in moderate-to-severe UC. Two reviewers independently extracted study data and outcomes, and investigated each trial's risk-of-bias. We used conventional meta-analysis to synthesise direct evidence, and network meta-analysis for adjusted indirect treatment comparisons. RESULTS: Fifteen randomised, double-blind, placebo-controlled trials (n = 3130) contributed data for induction: All treatments are superior to placebo. Indirect treatment comparisons showed that infliximab is better than adalimumab (OR: 2.01, 95% CI: 1.36-2.98) and golimumab (1.67, 1.08-2.59) in clinical response, better than adalimumab (2.10, 1.21-3.64) in clinical remission, and better than adalimumab (1.87, 1.26-2.79) and golimumab (1.75, 1.13-2.73) in mucosal healing. No indirect comparisons between tofacitinib and biologics reached statistical significance. Nine studies (n = 1776) contributed maintenance data showing that all treatments have higher clinical efficacy than placebo. Safety analyses indicated no increased rates of adverse events for the treatments under evaluation (except for infliximab), while vedolizumab may have an advantage regarding the occurrence of serious adverse events. CONCLUSIONS: Tofacitinib and biologics are efficacious and safe for UC. Further high-quality research is warranted to establish the best therapeutic option.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2017. PMID: 29205421. doi:10.1111/apt.14449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。